| 24.67 2.87 (13.17%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.09  |
1-year : | 33.98 |
| Resists | First : | 24.9 |
Second : | 29.09 |
| Pivot price | 19.33 |
|||
| Supports | First : | 19.87 |
Second : | 16.77 |
| MAs | MA(5) : | 21.45 |
MA(20) : | 18.98 |
| MA(100) : | 21.24 |
MA(250) : | 22.76 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 89.4 |
D(3) : | 86.8 |
| RSI | RSI(14): 70.2 |
|||
| 52-week | High : | 44.59 | Low : | 8.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZBIO ] has closed It is unclear right now based on current values. 45.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.94 - 25.03 | 25.03 - 25.11 |
| Low: | 21.71 - 21.82 | 21.82 - 21.9 |
| Close: | 24.49 - 24.67 | 24.67 - 24.82 |
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Thu, 25 Jun 2026
Enterprise value to EBIT forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Thu, 25 Jun 2026
Enterprise value to revenue forward of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
Wed, 17 Jun 2026
Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71 - Stock Titan
Wed, 17 Jun 2026
Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff - Stock Titan
Wed, 17 Jun 2026
Zenas BioPharma (ZBIO) awards options and ESPP shares to officer - Stock Titan
Wed, 17 Jun 2026
Zenas BioPharma (ZBIO) awards 150,000 stock options to officer - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 23.2 (%) |
| Held by Institutions | 90.4 (%) |
| Shares Short | 10,880 (K) |
| Shares Short P.Month | 10,850 (K) |
| EPS | -9.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -137.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -166 (M) |
| PE Ratio | -2.72 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|